Chargement en cours...

MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside

Small cell lung cancer (SCLC) is the most aggressive type of lung cancer. The different systemic treatment approaches attempted in the last 35 years have not improved overall survival in the advanced stage. Targeted therapies assessed in clinical trials have failed to show efficacy against SCLC. Wit...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancers (Basel)
Auteurs principaux: Hardy-Werbin, Max, del Rey-Vergara, Raúl, Galindo-Campos, Miguel Alejandro, Moliner, Laura, Arriola, Edurne
Format: Artigo
Langue:Inglês
Publié: MDPI 2019
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6827355/
https://ncbi.nlm.nih.gov/pubmed/31547040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11101404
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!